A Agilent Technologies Inc.

Agilent Announces Thought Leader Award to Professor Jennifer Field

(NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award. A professor in the Environmental and Molecular Toxicology Department at , Dr. Field focuses her research on the quantitative analysis of organic micropollutants and their transformation products in natural and engineered systems, particularly per- and polyfluoroalkyl substances (PFAS).

Commonly referred to as “forever chemicals”, PFAS have been widely used in various industrial applications since the 1940s. Recent studies have revealed that an increasing number of the over 5,000 identified PFAS chemicals pose a significant risk due to their resistance to biodegradation, potentially leading to harmful effects on both human health and wildlife. Thus, although their full toxicological and environmental implications remain the subject of intense research, detecting and identifying these substances in complex environmental matrices and commercial products is a pressing challenge.

Professor Field commented on the Agilent Thought Leader Award. “It is with profound gratitude that I receive this prestigious award. Our investigative efforts are centered on the multifaceted array of PFAS compounds. Despite some shared attributes, the structural diversity exhibited by this wide array of chemicals is remarkable and poses many challenges. We are on a quest to help discern which PFAS are present to help inform human exposure to PFAS by collecting data on PFAS occurrence, fate, and transport. Agilent’s state-of-the-art technologies will undoubtedly be an invaluable asset in this quest.”

As part of her multi-faceted research program in environmental analytical chemistry, Professor Field leads a team aiming to establish a hierarchical approach for the discovery, characterization, and quantification of PFAS present in groundwater, wastewater and other effluents, landfill leachates, commercial products, and consumer goods. To this end, they employ a strategy that combines gas- and liquid chromatography with high resolution mass spectrometry complemented by other analyses to characterize the total fluorine content of samples and to characterize fluoropolymers and their additives.

Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry division, remarked on the significance of recognizing Professor Field with this award. “We are privileged to support Professor Field. Her innovative approach to utilizing analytical methodologies to comprehend and alleviate the environmental and health repercussions of PFAS is truly commendable. Her work will undoubtedly significantly influence environmental conservation and global health.”

Under the guidance of Dr. Chong Wing Yung, Associate Director of Global University Relations and External Research at Agilent, the Agilent Thought Leader Award program is committed to fostering scientific advancement. This program supports esteemed thought leaders in the fields of life sciences, diagnostics, and chemical analysis by providing financial aid, products, and expertise. For more information, please visit the website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
13/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch